Shenzhen Tajirui Biopharmaceutical

About Shenzhen Tajirui Biopharmaceutical

Shenzhen Tajirui Biopharmaceutical, also known as TJR BIO, operates as a high-tech pharmaceutical research and development company. Established in 2018, it began as a Sino-American joint venture under the name Shenzhen TargetRx. The firm has secured funding from investors such as Shenzhen Capital Group, CCB Principal Capital Management, Oriental Fortune Capital, and CCB International.

The company functions as a Contract Development and Manufacturing Organization (CDMO), providing comprehensive, one-stop services for global clients in the nucleic acid drug sector. Its business model is centered on offering end-to-end solutions that span from initial drug development to full-scale production. The client base consists of pharmaceutical and biotechnology companies that require specialized support in bringing nucleic acid-based therapeutics to market. As a CDMO, revenue is generated by providing these specialized research, development, and manufacturing services.

TJR BIO's core services revolve around oligonucleotide research, development, and manufacturing. This includes the chemical modification of nucleic acids, the development of conjugated drugs like Antibody-Oligonucleotide Conjugates (AOC), and process and analytical method development. The company is proficient in producing Active Pharmaceutical Ingredients (API) and developing Lipid Nanoparticle (LNP) formulations for various nucleic acid drugs, such as small nucleic acids and mRNA. Its technical capabilities cover oligonucleotide synthesis, conjugation technology, and CMC process development, with demonstrated experience in scaling production from milligrams to kilograms for ASO, siRNA, PMO, and CpG oligonucleotides. The research and development team is directed by PhD-level scientists with extensive experience in the oligonucleotide field.